Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinichi Toyooka

Showing results (361-370 of 537) with videos related to

Pageof 54
Sort By:
Clinical Breast Cancer|October 2, 2019
Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast CancerYuko Takahashi, Takayuki Iwamoto, Yoko Suzuki, et al.
International Journal of Cancer|March 5, 2004
Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor typesNarayan Shivapurkar, Shinichi Toyooka, Kiyomi O Toyooka, et al.
Cancer Science|March 14, 2018
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterationsHidejiro Torigoe, Kazuhiko Shien, Tatsuaki Takeda, et al.
Oncogene|June 26, 2002
Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell linesKenichi Harada, Shinichi Toyooka, Anirban Maitra, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2011
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitorNaruyuki Kobayashi, Shinichi Toyooka, Junichi Soh, et al.
International Journal of Clinical Oncology|June 28, 2011
Ileal perforation induced by acute radiation injury under gefitinib treatmentTakayuki Muraoka, Kazunori Tsukuda, Shinichi Toyooka, et al.
Cancer Science|November 8, 2015
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterationsKen Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, et al.
Surgery Today|March 7, 2024
Impact of the neutrophil-to-lymphocyte ratio on patients with locally advanced non-small cell lung cancer who suffer radiation pneumonitis during the course of induction chemoradiotherapy followed by surgeryYujiro Kubo, Hiromasa Yamamoto, Kei Matsubara, et al.
Transplantation Direct|April 12, 2024
Postoperative Complications in Living Donors for Lung TransplantationShin Tanaka, Kento Fujii, Megumi Ishihara, et al.
Oncology Letters|March 12, 2019
Anti-tumor effect of neratinib against lung cancer cells harboring <i>HER2</i> oncogene alterationsYusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, et al.
Pageof 54

Showing results (361-370 of 537) with videos related to

Sort By:
Pageof 54
Clinical Breast Cancer|October 2, 2019
Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast CancerYuko Takahashi, Takayuki Iwamoto, Yoko Suzuki, et al.
International Journal of Cancer|March 5, 2004
Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor typesNarayan Shivapurkar, Shinichi Toyooka, Kiyomi O Toyooka, et al.
Cancer Science|March 14, 2018
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterationsHidejiro Torigoe, Kazuhiko Shien, Tatsuaki Takeda, et al.
Oncogene|June 26, 2002
Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell linesKenichi Harada, Shinichi Toyooka, Anirban Maitra, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2011
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitorNaruyuki Kobayashi, Shinichi Toyooka, Junichi Soh, et al.
International Journal of Clinical Oncology|June 28, 2011
Ileal perforation induced by acute radiation injury under gefitinib treatmentTakayuki Muraoka, Kazunori Tsukuda, Shinichi Toyooka, et al.
Cancer Science|November 8, 2015
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterationsKen Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, et al.
Surgery Today|March 7, 2024
Impact of the neutrophil-to-lymphocyte ratio on patients with locally advanced non-small cell lung cancer who suffer radiation pneumonitis during the course of induction chemoradiotherapy followed by surgeryYujiro Kubo, Hiromasa Yamamoto, Kei Matsubara, et al.
Transplantation Direct|April 12, 2024
Postoperative Complications in Living Donors for Lung TransplantationShin Tanaka, Kento Fujii, Megumi Ishihara, et al.
Oncology Letters|March 12, 2019
Anti-tumor effect of neratinib against lung cancer cells harboring <i>HER2</i> oncogene alterationsYusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, et al.
Pageof 54